guided entry of tail-anchored proteins factor 1Genealiases: CHD5 · WRB
Q-omics provides the consensus-scored GET1 profile across patient tissues and cancer cell-line models. GET1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, GET1 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, GET1 RNA expression shows 19,715 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, and ACC as cancer lineages where GET1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GET1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GET1 survival associations across molecular data types. GET1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GET1 RNA expression–survival associations across cancer types. High GET1 expression shows unfavorable associations in KICH, SCLC and CHOL, but favorable associations in KIRC, LUAD and UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for GET1 RNA expression.
This table summarizes GET1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for GET1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GET1 shows lower tumor expression in KICH and LUSC and higher tumor expression in KIRC, LIHC, BRCA and COAD. The KIRC box plot shows higher GET1 RNA expression in tumor versus normal tissue (log2 FC = +0.539, t-test p < 0.001).
This table shows molecular features associated with GET1 in patient tissues and cancer cell lines. In patient samples, GET1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, GET1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and UPPER_AERODIGESTIVE_TRACT.
